Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of HCV-796 in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults
  • Phase

    Phase 1
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    nesbuvir ...
  • Study Participants

The purpose of this study is to assess the pharmacokinetics (PK) of HCV-796 in subjects with chronic hepatic impairment and in matched healthy adults.
Study Started
May 31
Primary Completion
Oct 31
Study Completion
Oct 31
Last Update
Apr 14

Drug HCV-796

HCV-796 1000mg single dose

1 Experimental

HCV-796 1000mg single dose


Inclusion Criteria:

Men and women of non-childbearing potential.
Hepatic impairment subjects: Child-Pugh class A, B, or C according to the C-P classification based on history, physical examination, and laboratory test results.
Healthy volunteers: healthy as determined by the investigator.

Exclusion Criteria:

History of alcoholism within 1 year.
Hepatic impairment subjects: evidence of unstable clinically significant disease other than impaired hepatic function.
Healthy volunteers: positive serologic findings for hepatitis B surface antigen (HBsAg) and/or hepatitis C virus (HCV) antibodies.
No Results Posted